Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement
International Journal of Clinical Oncology · 2024-10 · 29 (10) · 1586-1593
DOI: 10.1007/s10147-024-02580-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 08.07.2024. Verfasst von Tokiyoshi Tanegashima und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Lymphatic Metastasis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The therapeutic role of pelvic lymph node dissection (PLND) during radical prostatectomy (RP) for prostate cancer is not established. In clinical practice, PLND is primarily performed in cases of high-risk prostate cancer. The detection of lymph node metastasis plays a crucial role in determining the need for subsequent treatments. This study aims to evaluate the prognosis of prostate cancer patients with lymph node involvement (LNI) by stratifying them based on postoperative prostate-specific antigen (PSA) levels to identify biomarkers that can guide postoperative treatment strategies. METHODS: Analysis was conducted on 383 patients, selected from 572 initially eligible, who underwent RP with LNI across 33 Japanese Urological Oncology Group institutions from 2006 to 2019. Patients were grouped according to postoperative PSA levels and salvage treatments received. Follow-up focused on castration resistance-free survival (CRFS), metastasis-free survival (MFS), and overall survival (OS). RESULTS: In the persistent PSA group (PSA ≥ 0.1 ng/mL), CRFS and MFS were significantly shorter compared to the non-persistent PSA group (PSA < 0.1 ng/mL), and there was a tendency for shorter OS. In the persistent PSA group, patients with postoperative PSA values above the median (PSA ≥ 0.52 ng/mL) showed shorter CRFS and MFS. Furthermore, in the PSA ≥ 0.52 group, androgen deprivation therapy (ADT) plus radiotherapy (RT) combination had prolonged CRFS and MFS compared with ADT alone. CONCLUSIONS: This study provides valuable insights into stratifying patients based on postoperative PSA levels to tailor postoperative treatment strategies, potentially improving the prognosis of prostate cancer patients with LNI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. shiota.masaki.101@m.kyushu-u.ac.jp.
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Urology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Urology, Harasanshin Hospital, Fukuoka, Japan.
- Department of Urology and Andrology, Kansai Medical University, Osaka, Japan.
Zitieren
APA
Tanegashima, T., Shiota, M., Kimura, T., Takamatsu, D., Matsui, Y., Yokomizo, A., Saito, R., Morizane, S., Miyake, M., Tsutsumi, M., Yamamoto, Y., Tashiro, K., Tomida, R., Edamura, K., Narita, S., Yamaguchi, T., Kasahara, T., Hashimoto, K., Kato, M., …, & Japanese Urological Oncology Group (2024). Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement. International Journal of Clinical Oncology, 29(10), 1586-1593. https://doi.org/10.1007/s10147-024-02580-6
Vancouver
Tanegashima T, Shiota M, Kimura T, Takamatsu D, Matsui Y, Yokomizo A, et al. Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement. International Journal of Clinical Oncology. 2024;29(10):1586-1593. doi:10.1007/s10147-024-02580-6
BibTeX
@article{Tanegashima2024,
author = {Tanegashima, Tokiyoshi and Shiota, Masaki and Kimura, Takahiro and Takamatsu, Dai and Matsui, Yoshiyuki and Yokomizo, Akira and Saito, Ryoichi and Morizane, Shuichi and Miyake, Makito and Tsutsumi, Masakazu and Yamamoto, Yoshiyuki and Tashiro, Kojiro and Tomida, Ryotaro and Edamura, Kohei and Narita, Shintaro and Yamaguchi, Takahiro and Kasahara, Takashi and Hashimoto, Kohei and Kato, Masashi and Yoshino, Takayuki and Akamatsu, Shusuke and Matsukawa, Akihiro and Kaneko, Tomoyuki and Matsumoto, Ryuji and Joraku, Akira and Kato, Manabu and Saito, Toshihiro and Kato, Takuma and Tatarano, Shuichi and Sakamoto, Shinichi and Kanno, Hidenori and Terada, Naoki and Nishiyama, Naotaka and Kitamura, Hiroshi and Eto, Masatoshi and Japanese Urological Oncology Group, Japanese Urological Oncology Group},
title = {Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement},
journal = {International Journal of Clinical Oncology},
year = {2024},
volume = {29},
number = {10},
pages = {1586--1593},
doi = {10.1007/s10147-024-02580-6}
}
EUVIMED